natgillin/translations-raw huggingface dataset:
coughing up blood
izkašljevanje krvi;
coughing up blood (common side effect),
izkašljevanje krvi (pogosti neželeni učinek),
coughing up blood (haemoptysis)
izkašljevanje krvi (hemoptiza)
Coughing up blood or blood in your sputum.
Če izkašljate kri ali opazite kri v sputumu.
Coughing up blood or blood-stained mucus from the airways.
Izkašljevanje krvi ali krvave sluzi iz dihalnih poti.
coughing up blood, producing more sputum than normally, chest discomfort, asthma, fever
izkašljevanje krvi, nastajanje več izpljunkov kot običajno, nelagodje v prsnem košu, astma, povišana telesna temperatura
Coughing up blood, wheezing, chest discomfort, asthma, productive cough (a cough which brings up mucus), infection of the lungs, lung crackles (your doctor would hear this when listening to your lungs using a stethoscope)
izkašljevanje krvi, sopenje, nelagodje v prsnem košu, astma, produktiven kašelj (kašelj, pri katerem se izpljuva sluz), okužba pljuč, šumi na pljučih (sliši jih vaš zdravnik, ko pljuča posluša s stetoskopom),
coughing up of blood or blood clots
izkašljevanje krvi ali krvnih strdkov
Coughing up of blood.
izkašljevanje krvi
coughing up or bringing up blood (uncommon)
izkašljevanje ali izpljuvanje krvi (občasno)
Coughing with phlegm, chest discomfort, fever (signs of lung disorders)
kašljanje z izkašljevanjem sluzi, občutek nelagodja v prsnem košu in zvišana telesna temperatura (znaki pljučnih bolezni),
coughing, sore nose
kašelj, vnet nos
coughing.
kašelj
Coughing;
kašelj;
Coughj
kašeljj
could be signs of a severe allergic reaction. experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.
To so lahko znaki hude alergijske reakcije. opazite zabuhlost obraza ali gležnjev, kri v urinu ali rjavo obarvan urin, ali če opazite, da urinirate manj kot običajno.
could become pregnant;
bi lahko zanosile;
could potentiate tenofovir
lahko povečala z njim povezane
could potentiate tenofovir associated adverse events, including renal
učinke, vključno z ledvičnimi motnjami.
coumarin anticoagulants for thinning the blood ( e.g. warfarin)
kumarinski antikoagulanti za redčenje krvi (npr, varfarin),
coumarin anticoagulants statins
kumarinskimi antikoagulanti
Coumarin-derivative anticoagulants.
Kumarinski antikoagulanti
Coumarin-derivative anticoagulation
Antikoagulantno zdravljenje s kumarinskimi derivati
coumarin-type anticoagulants, such as warfarin or phenprocoumon,
kumarine, kot sta varfarin ali fenprokumon,
Count each half of the strip with a suitable radioactivity counting apparatus (dose calibrator or multichannel analyzer).
Vsako polovico lističa odčitajte z ustreznim aparatom za merjenje radioaktivnosti (umerjevalnikom odmerka ali večkanalnim analizatorjem).
Count each strip section in a dose calibrator and interpret the results as follows: Percent technetium-99m non-mobile material = A
Odčitajte štetje za vsak kos traku v kalibratorju odmerka in interpretirajte rezultate kot sledi:
COUNT TO FIVE to ensure that all of the solution is injected.
PREŠTEJTE DO PET, da boste zagotovili, da je bila injicirana vsa raztopina.
counter stopped: 52 units
odmerka se je ustavil: ostalo je še
counter stopped: 52 units
števec odmerka se je ustavil: ostalo je še
Countries Period (Age)
Država Obdobje (starost)
Country (year of introduction)
Država (leto uvedbe)
Counts (activity) in bottom half Counts(activity) in bottom half + Counts(activity) in top half
+ izmera (aktivnosti) na zgornji polovici
Counts (percentages) corresponds to the number of patients reporting the event
Številke (odstotki) ustrezajo številu bolnikov, ki so poročali o dogodku.
County Durham DL12 8DT United Kingdom.
County Durham DL12 8DT Velika Britanija
County Durham DL12 8DT United Kingdom.
County Durham, DL12 8DT Velika Britanija
County Durham DL12 8DT, United Kingdom.
County Durham DL12 8DT Velika Britanija
County Durham, DL12 8DT United Kingdom.
County Durham, DL12 8DT Velika Britanija
Covariates as baseline PASI, baseline lymphocyte count and age had modest effects on clearance; gender and ethnic origin had no effect.
Kovariable kot so izhodiščni PASI, izhodiščno število limfocitov in starost so le malo vplivale na očistek; spol in etično poreklo nista imela vpliva.
Cover
Zavarujte
cover as much skin as possible by wearing a long-sleeved shirt, trousers, socks, shoes, gloves and a wide brimmed hat
zakrijte si čim večji del kože tako, da nosite srajco z dolgimi rokavi, hlače, nogavice, čevlje, rokavice in širokokrajni klobuk,
cover as much skin as possible by wearing a long-sleeved shirt, trousers, socks, shoes, gloves and a wide brimmed hat
zakrijte si čim večji del kože tako, da nosite srajco z dolgimi rokavi, hlače, nogavice, čevlje, rokavice in širokokrajni klobuk.
Cover letter
premno pismo,
Cover the tank and allow to equilibrate for at least 5 minutes.
Kopel pokrijte in omogočite, da izenačevanje temperature traja vsaj 5 minut.
Cover the tanks and allow to equilibrate with the solvent vapours.
Pokrijte in počakajte, da se uravnotežijo pare topila.
Cover the ulcer with a moist saline (salt) gauze dressing.
Razjedo prekrijte z obkladkom iz gaze, namočene v fiziološko raztopino.
COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.
COX-2 so pri človeku odkrili v tkivu okoli želodčnih razjed, vendar njen pomen za celjenje razjed ni znan.
COX-2 inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.
Ker selektivni zaviralci COX-2 nimajo antiagregacijskega delovanja, niso nadomestilo za acetilsalicilno kislino v profilaksi kardiovaskularnih trombemboličnih bolezni.
COX-2 inhibitors have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term.
Dolgotrajna uporaba zaviralcev COX-2 je bila povezana s povečanim tveganjem za srčnožilne in trombotične neželene učinke.
COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function).
COX-2 je vpletena tudi v ovulacijo, implantacijo, zaprtje ductusa arteriosusa, regulacijo delovanja ledvic in v nekatere funkcije osrednjega živčevja (sprožitev zvišane telesne temperature, zaznavanje bolečine in kognitivne funkcije).
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception and cognitive function).
COX – 2 naj bi sodeloval tudi pri ovulaciji, implantaciji in zaprtju ductusa arteriosusa, ter pri delovanju centralnega živčnega sistema (sprožitev povišane telesne temperature, zaznava bolečine in sposobnosti zaznave).
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception, and cognitive function).
Za COX-2 se domneva tudi, da je vključen v procesu ovulacije, implantacije in zaprtju zaptje ductus arteriosus ter v funkcije osrednjega živčnega sistema (indukcija vročine, zaznavanje bolečine in kognitivne funkcije).
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception, and cognitive function).
Za COX-2 se domneva tudi, da je vpleten v procesu ovulacije, implantacije, zaprtju duktusa ductus arteriosus in v funkcije osrednjega živčnega sistema (indukcija vročine, percepcija bolečine in kognitivne funkcije).
COX-2 is the inducible form of the enzyme and is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever.
COX-2 je inducibilna oblika encima, ki je odgovorna za sintezo mediatorjev, vključno s PGE2, ki inducirajo bolečino, vnetje ali povišano telesno temperaturo.
COX-2 is the isoform of the enzyme that has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
COX-2 je izoformna oblike encima, ki je po ugotovitvah v največji meri odgovoren za sintezo prostanoidnih mediatorjev bolečine, vnetja in povišane telesne temperature.
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
COX-2 je izoforma encima, za katerega se je izkazalo, da je induciran z dražljaji, ki delujejo v smeri nastanka vnetja, in za katerega se domneva, da je primarno odgovoren za sintezo prostanoidnih mediatorjev za bolečino, vnetje in vročino.
Coxevac was initially authorised under ‘exceptional circumstances’.
Zdravilo Coxevac je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
Cox’s Proportional Hazard Ratio [95% CI]
Sorazmerno razmerje tveganja po Coxu [95% IZ]
Co–administration may result in decreased plasma concentrations of indinavir and as a consequence an increased risk for suboptimal treatment and facilitation of development of resistance (see section 4.5).
Pri sočasnem jemanju lahko pride do zmanjšanja plazemskih koncentracij indinavirja in posledično do zvečanja tveganja za suboptimalno zdravljenje in lažjega razvoja rezistence (glejte poglavje 4.5).
Co–administration of CRIXIVAN with sildenafil, tadalafil and vardenafil (PDE5 inhibitors) are expected to substantially increase the plasma concentrations of these compounds and may result in an increase in PDE5 inhibitor–associated adverse events, including hypotension, visual changes, and priapism (see section 4.5).
Pri sočasni uporabi zdravila CRIXIVAN in sildenafila, tadalfila in vardenafila (zaviralcev PDE5) pričakujemo znatno povečanje plazemskih koncentracij teh snovi, kar lahko povzroči več z zaviralci PDE5 povezanih neželenih učinkov, vključno s hipotenzijo, spremembami vida in priapizemom (glejte poglavje 4.5).
co–administration with saquinavir
Interakcija
CP 1 g/m2 i.v. (1 h), days 26, 46;
CP 1 g/m2 i.v. (1 ura), 26., 46. dan;
CP 1 g/m2 i.v. (1 h), days 26, 46;
CP 1 g/m² i.v. (1 ura), 26., 46. dan;
CP 1.2 g/ m2 i.v. (3 h), day 1;
CP 1,2 g/m2 i.v. (3 ure), 1. dan;
CP 1.2 g/m2 i.v. (3 h), day 1;
CP 1,2 g/m2 i.v. (3 ure), 1. dan;
CP 1.2 g/m2 i.v. (3 h), day 1;
CP 1,2 g/m² i.v. (3 ure), 1. dan;
CP 200 mg/ m2 i.v., days 3, 4, 5;
CP 200 mg/m2 i.v., 3., 4., 5. dan;
CP 200 mg/m2 i.v., days 3, 4, 5;
CP 200 mg/m2 i.v., 3., 4., 5. dan;
CP 200 mg/m2 i.v., days 3, 4, 5;
CP 200 mg/m² i.v., 3., 4., 5. dan;
CP 200 mg/m2 i.v., days 3-5;
CP 200 mg/m2 i.v., 3.-5. dan;
CP 200 mg/m2 i.v., days 3-5;
CP 200 mg/m² i.v., 3.-5. dan;
CP A or B
CP A ali B
CP arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles of 3 weeks duration
CP skupina: 6 tritedenskih ciklov karboplatina (AUC 6) in paklitaksela (175 mg/m2)
CP classes
CP razredi
CP-AI-005 enrolled 246 adult (predominantly) and paediatric patients.
V študiji CP-AI-005 je sodelovalo 246 odraslih (v večini) in pediatričnih bolnikov.
CP-CML (N=270) (%)
CP-KML (N = 270) (%)
CP-Pharma Handelsgesellschaft mbH, Germany
CP-Pharma Handelsgesellschaft mbH, Nemčija
CPB15 arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
CPB15 skupina: pet ciklov zdravila Avastin (15 mg/kg telesne mase enkrat na 3 tedne, z začetkom v ciklu 2) v kombinaciji s karboplatinom (AUC 6) in 6 cikli paklitaksela (175 mg/m2), katerim je sledil samo placebo do skupno 15 mesecev zdravljenja.
CPB15+ arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by continued use of Avastin (15 mg/kg q3w) as single agent for a total of up to 15 months of therapy.
CPB15+ skupina: pet ciklov zdravila Avastin (15 mg/kg telesne mase enkrat na 3 tedne, z začetkom v ciklu 2) v kombinaciji s karboplatinom (AUC 6) in 6 cikli paklitaksela (175 mg/m2), katerim je sledilo zdravljenje samo z zdravilom Avastin (15 mg/kg telesne mase enkrat na 3 tedne) do skupno 15 mesecev zdravljenja.
CPB7.5+ arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles of 3 weeks plus Avastin (7.5 mg/kg q3w) for up to 12 months (Avastin was started at cycle 2 of chemotherapy if treatment was initiated within 4 weeks of surgery or at cycle 1 if treatment was initiated more than 4 weeks after surgery).
CPB7,5 + skupina: 6 tritedenskih ciklov karboplatina (AUC 6) in paklitaksela (175 mg/m2) ter zdravila Avastin (7,5 mg/kg telesne mase enkrat na 3 tedne) do 12 mesecev (zdravljenje z zdravilom Avastin se je začelo pri drugem ciklu kemoterapije, če se je s terapijo začelo v prvih 4 tednih po operaciji ali pri prvem ciklu, če se je s terapijo začelo več kot 4 tedne po operaciji).
CPK elevations and rhabdomyolysis: CPK elevations of any grade were observed in 23-26% of patients in both regimens.
Zvišanje CPK in rabdomioliza: Pri 23 %-26 % bolnikov pri obeh režimih so opazili zvišanje CPK katerekoli stopnje.
CPK increase is labelled as a common ADR in section 4.8 of the SmPC of leflunomide (Arava).
Povišane vrednosti CPK so navedene kot pogosti neželeni učinek v poglavju 4.8 SmPC leflunomida (zdravilo Arava).
CPK increases in association with rhabdomyolysis were reported in less than 1% of patients.
O zvišanju CPK v povezavi z rabdomiolizo so poročali pri manj kot 1 % bolnikov.
CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy.
Pri bolnikih z večjim tveganjem za nastanek miopatij je treba CPK meriti bolj pogosto (na primer vsake 2 do 3 dni, vsaj v prvih dveh tednih zdravljenja).
CPM (250 mg/m2/dose q12h x 4 doses, iv): Days 3 and 4
CPM (250 mg/m2/odmerek vsakih 12 ur x 4 odmerki, i.v.): 3. in 4. dan
CPM (300 mg/m2, IV): days 29-33 MESNA IV days 29-33
CPM (300 mg/m2 i.v.): 29.-33. dan MESNA i.v.: 29.-33. dan
CPM (300 mg/m2/day, IV): days 22-26
CPM (300 mg/m2/dan, i.v.): 22.-26. dan
CPP arm: Five cycles of placebo (started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
CPP skupina: pet ciklov placeba (z začetkom v ciklu 2) v kombinaciji s karboplatinom (AUC 6) in 6 cikli paklitaksela (175 mg/m2), katerim je sledil samo placebo do skupno 15 mesecev zdravljenja.
Cpredose μg /mL
Cpred odmerkom μg /ml
CPT = Child-Pugh-Turcotte.
CPT = po Child-Pugh-Turcotteu.
CPT Class C cirrhosis
Ciroza jeter stopnje C po CPT
CPT Class C cirrhosis pre-transplant CPT Class B or C post-transplant
S cirozo jeter stopnje C po CPT pred presaditvijo
CR
14,3
CR
PR
CR (%)
Popolni odziv (%)
CR + CRp + PR
PR + PRt + DR
CR 2 mg total dose i.v., days 1, 8, 15, 22;
VCR skupni odmerek 2 mg i.v., 1., 8., 15., 22. dan;
CR = Complete Remission
PR = Popolna remisija
CR = complete remission; CRp = complete remission with incomplete platelet recovery, EFS = event-free survival, PFS = progression-free survival, OR = odds ratio, HR = hazard ratio
CR = popolna remisija (complete remission); CRp = popolna remisija z nepopolno normalizacijo vrednosti trombocitov (complete remission with incomplete platelet recovery), OR = razmerje obetov (odds ratio), HR = razmerje tveganja (hazard ratio)
CR was defined as  5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/microlitre and absolute neutrophil counts [ANC]
Popolna remisija (CR) je bila opredeljena kot  5 % blastov v kostnem mozgu, brez znakov bolezni in popolno okrevanje periferne krvne slike (trombociti > 100.000/mikroliter in absolutno število nevtrofilcev
CR with MRD Negativity (% of CR)
Popolni odziv z negativno MRD (% popolnega odziva)
CR+nCR
(10)
CR+nCR
14,6 (10,4; 19,7)
CR+nCR
49,2 (40,4; 58,1)
CR+nCR+PR
(27)
CR+nCR+PR
CR+ nCR + PR
CR+nCR+VGPR+PR
CR+nCR+VGPR+PR
CR+PR+MR **CR=CR, (IF-); nCR=CR (IF+)
CR+PR+MR; **CR=CR, (IF-); nCR=CR (IF+)
Cr: creatinine; ULN: upper limit of normal
ZMN: zgornja meja normalnih vrednosti
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat
CR=popolni odgovor; CRu=nepotrjen popšolni odgovor; PR=delni odgovor; CI=interval zaupanja, HR=razmerje tveganja; OR=razmerje verjetnosti; ITT=populacija, ki so jo nameravali zdraviti
CR=Complete Response; nCR=near Complete response PR=Partial Response; MR=Minimal response
CR=popolni odgovor; nCR=skoraj popolni odgovor PR=delni odgovor; MR=minimalni odgovor
Cracking of the corner of the mouth, swollen gums, salivary gland pain
razpoke v kotičkih ustnic, oteklina dlesni, bolečina žleze slinavke,
Cracking, scabbing, crusting, draining, oozing Pain, burning, soreness
Pokanje kože, nastajanje krast, krastavost, izločanje tekočine, izcedki Bolečina, pekoča bolečina, občutljivost
CRAD001C2485: This was a prospective, open-label, single-arm phase II study of everolimus in patients with SEGA (n=28).
CRAD001C2485: To je bila prospektivna, odprta študija everolimusa faze II pri eni skupini bolnikov s SEGA (n=28).
Cramlington Northumberland NE23 3JU United Kingdom
Cramlington Northumberland NE23 3JU Velika Britanija
cramp in muscles
krči v mišicah,
cramps and muscle pains skin rash or ‘hives’ anywhere on the body
krči in bolečine v mišicah kožni izpuščaji ali ‘koprivnica’ kjerkoli po telesu
cramps and muscle pains skin rash or ‘hives’ anywhere on the body
krči in bolečine v mišicah; kožni izpuščaji ali ‘koprivnica’ kjerkoli po telesu.
cramps or painful, tender or weak muscles - these may be signs of muscle inflammation or breakdown, which can cause kidney damage or even death
krči ali boleče, občutljive ali šibke mišice - to so lahko znaki vnetja ali razpadanja mišic, ki lahko povzroči poškodbe ledvic ali celo smrt,
cranial
kranialna
Cranial irradiation (Block 5 only)
obsevanje glave (samo 5. blok)
Craniosynostosis as a manifestation of hypophosphatasia is documented in published literature and occurred in 61.3% of patients between birth and 5 years of age in a natural history study of untreated infantile-onset hypophosphatasia patients.
Kraniosinostoza kot manifestacija hipofosfatazije je dokumentirana v objavljeni literaturi in se je pojavila pri 61,3 % bolnikov med rojstvom in 5. letom starosti v študiji naravnega poteka bolezni pri bolnikih z nezdravljeno hipofosfatazijo z infantilnim nastopom.
CrCL (ml/min)b 93.8
CrCL (ml/min)b 93,8
CrCL < 15 mL/min), to use the correct Lixiana dose in patients with CrCL 15 – 50 mL/min (30 mg once daily), in patients with CrCL > 50 mL/min (60 mg once daily) and when deciding on the use of Lixiana in patients with increased creatinine clearance (see section 4.4).
CrCL < 15 ml/min) in da uporabite pravilen odmerek zdravila Lixiana pri bolnikih s CrCL 15 - 50 ml/min (30 mg enkrat na dan) in pri bolnikih s CrCL > 50 ml/min (60 mg enkrat na dan), ter takrat, ko se odločate glede uporabe zdravila Lixiana pri bolnikih z zvišanim očistkom kreatinina (glejte poglavje 4.4).
CrCL < 30 mL/min) (see sections 4.3, 4.4 and 5.2).
CrCl < 30 ml/min) (glejte poglavja 4.3, 4.4 in 5.2).
CrCl < 50 ml/minute
2 x začetna vrednost in
CrCl < 60mL/min as it has not been studied in this population (see sections 4.4 and 5.2).
CrCl < 60 ml/min, ker pri tej populaciji študije niso bile opravljene (glejte poglavji 4.4 in 5.2).
CrCl <70 mL/min (n=214)
Očistek kreatinina < 70 ml/min (n = 214)
CrCl = (140 – age) x weight/72 x serum creatinine [x 0.85 for females], where age is in years, weight in kg, and serum creatinine is in mg/dl.
Cockcroft-Gaultovi formuli: CrCl = [140 – starost] x telesna masa/72 x serumski kreatinin [x 0,85 pri ženskah], kjer je starost je v letih, telesna masa v kg in serumski kreatinin v mg/dl.
CrCl = 30-49 ml/min and severe with CrCl = 10-29 ml/min).
CLCR = 30-49 ml/min in resna pri CLCR = 10-29 ml/min).
CrCl must be calculated at the beginning of every cycle before the start of treatment with Teysuno on Day 1.
Vrednost CrCl je treba izračunati na začetku posameznega cikla, in sicer na 1. dan pred začetkom zdravljenja z zdravilom Teysuno.
CrCL should be closely monitored and the dose adjusted according to changing renal function c The dose administered every 8 hours should not exceed 300 mg d The dose administered every 8 hours should not exceed 200 mg
Očistek kreatinina je treba skrbno spremljati in odmerek prilagoditi glede na spreminjajoče se delovanje ledvic. c Odmerek, uporabljen na 8 ur, ne sme preseči 300 mg. d Odmerek, uporabljen na 8 ur, ne sme preseči 200 mg.
CrCL ≥ 30-< 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCl ≥ 30 - < 50 ml/min, zdravljenje z antagonistom vitamina K začnite 2 dni pred ukinitvijo dabigatran eteksilata.
CrCL ≥ 30-< 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCl ≥ 30-< 50 ml/min, zdravljenje z antagonistom vitamina K začnite 2 dni pred ukinitvijo dabigatran eteksilata.
CrCL ≥ 50 mL/min, start VKA 3 days before discontinuing dabigatran etexilate
CrCl ≥ 50 ml/min, zdravljenje z antagonistom vitamina K začnite 3 dni pred ukinitvijo dabigatran eteksilata;
CrCl ≥70 mL/min (n=227)
Očistek kreatinina ≥ 70 ml/min (n = 227)
Cream
11,5
Cream 15 g
krema 15 g
Create a solution with a concentration of 4 mg/ml following the dilution guidelines below: Patients ≤ 100 kg: 25 ml of BRINAVESS 20 mg/ml is added to 100 ml of diluent.
Pripravite raztopino s koncentracijo 4 mg/ml z upoštevanjem naslednjih navodil za redčenje: Bolniki s telesno maso ≤ 100 kg: 25 ml zdravila BRINAVESS 20 mg/ml dodajte 100 ml vehikla.
Create a solution with a concentration of 4 mg/ml following the dilution guidelines below: Patients ≤100 kg: 25 ml of BRINAVESS 20 mg/ml is added to 100 ml of diluent.
Pripravite raztopino s koncentracijo 4 mg/ml z upoštevanjem naslednjih navodil za razredčenje: Bolniki s telesno maso ≤ 100 kg: 25 ml zdravila BRINAVESS 20 mg/ml dodajte 100 ml vehikla.
Creatine phosphokinase (CPK) elevations
zvišane vrednosti kreatin-fosfokinaze (CPK)
Creatine phosphokinase (CPK) elevations
Zvišanja kreatin-fosfokinaze (CPK)
Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).
Koncentracijo kreatin-fosfokinaze (CPK) je treba izmeriti pred začetkom zdravljenja in nato v rednih intervalih med zdravljenjem (vsaj enkrat tedensko) (glejte poglavje 4.4).
Creatine phosphokinase (CPK)  2.5 x ULN
Kreatin fosfokinaza (CPK)  2,5 x ULN
Creatine phosphokinase and myopathy
Kreatin-fosfokinaza in miopatija
Creatine phosphokinase increased
povišana raven kreatin- fosfokinaze
Creatinine
Alaninaminotransferaz a (ALT)
Creatinine <2.5 mg/dl
Kreatinin <2.5 mg/dl
Creatinine Clearance
Kreatininski očistek
Creatinine clearance
očistek kreatinina
Creatinine clearance
očistek kreatinina (ml/min/1,73m2)
Creatinine clearance (CLcr) (ml/min)
očistek kreatinina (CLcr) (ml/min)
Creatinine clearance (CLcr) (ml/min)
očistek kreatinina (OČkr) (ml/min)
Creatinine clearance (CrCl) must be determined for every cycle before the start of treatment on Day 1.
Očistek kreatinina (CrCl) je treba določiti za vsak cikel na 1. dan pred začetkom zdravljenja.
Creatinine clearance (ml/min/1.73 m2)
očistek kreatinina
Creatinine clearance (ml/min/1.73 m2)
očistek kreatinina (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73m2 )
očistek kreatinina (ml/min/1,73m2)
Creatinine clearance (ml/min/1.73m2)
očistek kreatinina
Creatinine clearance (ml/min/1.73m2)
očistek kreatinina (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73m2)
očistek kreatinina (ml/min/1,73m2)
Creatinine clearance < 15 mL/min (or creatinine clearance decreases to ≤ 50% of baseline) or need for dialysis
Očistek kreatinina < 15 ml/min (ali zmanjšanje očistka kreatinina na
Creatinine clearance and/or plasma cystatin C
očistek kreatinina in/ali cistatin C v serumu
Creatinine clearance decreased**
Znižan očistek
Creatinine clearance decreased**
Znižan očistek kreatinina
Creatinine clearance decreased, nephritis, haematuria
zmanjšan očistek kreatinina, nefritis,
Creatinine clearance decreased, nephritis, haematuria
zmanjšan očistek kreatinina, nefritis, hematurija